Astrazeneca (AZN) Current Leases (2017 - 2025)

Astrazeneca (AZN) has reported Current Leases for 8 consecutive years, with $382.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Leases rose 12.68% year-over-year to $382.0 million; the TTM figure through Dec 2025 stood at $382.0 million (up 12.68% YoY), while the FY2025 annual figure was $382.0 million, up 12.68% from the prior year.
• Current Leases came in at $382.0 million for Q4 2025 at Astrazeneca, up from $339.0 million in the prior quarter.
• The five-year high for Current Leases was $382.0 million in Q4 2025, with the low at $228.0 million in Q4 2022.
• Average Current Leases over 5 years is $290.6 million, with a median of $271.0 million recorded in 2023.
• Across the five-year window, Current Leases retreated 2.15% in 2022 and rose 25.09% in 2024, its largest moves.
• Year by year, Current Leases stood at $233.0 million in 2021, then declined by 2.15% to $228.0 million in 2022, then advanced by 18.86% to $271.0 million in 2023, then grew by 25.09% to $339.0 million in 2024, then rose by 12.68% to $382.0 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $382.0 million, $339.0 million, and $271.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.